These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36157209)

  • 1. Meta-Analysis of the Prognostic and Predictive Role of the CpG Island Methylator Phenotype in Colorectal Cancer.
    Wang J; Deng Z; Lang X; Jiang J; Xie K; Lu S; Hu Q; Huo Y; Xiong X; Zhu N; Zhang W
    Dis Markers; 2022; 2022():4254862. PubMed ID: 36157209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis.
    Juo YY; Johnston FM; Zhang DY; Juo HH; Wang H; Pappou EP; Yu T; Easwaran H; Baylin S; van Engeland M; Ahuja N
    Ann Oncol; 2014 Dec; 25(12):2314-2327. PubMed ID: 24718889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review.
    Jia M; Gao X; Zhang Y; Hoffmeister M; Brenner H
    Clin Epigenetics; 2016; 8():25. PubMed ID: 26941852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No association of CpG island methylator phenotype and colorectal cancer survival: population-based study.
    Jia M; Jansen L; Walter V; Tagscherer K; Roth W; Herpel E; Kloor M; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M
    Br J Cancer; 2016 Nov; 115(11):1359-1366. PubMed ID: 27811854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG island methylator phenotype is an independent predictor of survival after curative resection for colorectal cancer: A prospective cohort study.
    Kim CH; Huh JW; Kim HR; Kim YJ
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1469-1474. PubMed ID: 28087988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer.
    Chen KH; Lin LI; Tseng LH; Lin YL; Liau JY; Tsai JH; Liang JT; Lin BR; Cheng AL; Yeh KH
    Oncology; 2019; 96(3):156-163. PubMed ID: 30540994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients.
    Fu T; Liu Y; Li K; Wan W; Pappou EP; Iacobuzio-Donahue CA; Kerner Z; Baylin SB; Wolfgang CL; Ahuja N
    Oncotarget; 2016 Dec; 7(52):86480-86489. PubMed ID: 27880934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.
    Jover R; Nguyen TP; Pérez-Carbonell L; Zapater P; Payá A; Alenda C; Rojas E; Cubiella J; Balaguer F; Morillas JD; Clofent J; Bujanda L; Reñé JM; Bessa X; Xicola RM; Nicolás-Pérez D; Castells A; Andreu M; Llor X; Boland CR; Goel A
    Gastroenterology; 2011 Apr; 140(4):1174-81. PubMed ID: 21185836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
    Min BH; Bae JM; Lee EJ; Yu HS; Kim YH; Chang DK; Kim HC; Park CK; Lee SH; Kim KM; Kang GH
    BMC Cancer; 2011 Aug; 11():344. PubMed ID: 21827707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of CpG island methylator phenotype among hepatocellular carcinoma patients: A systematic review and meta-analysis.
    Wang Q; Wang G; Liu C; He X
    Int J Surg; 2018 Jun; 54(Pt A):92-99. PubMed ID: 29698791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG island methylator phenotype and prognosis of colorectal cancer in Northeast China.
    Li X; Hu F; Wang Y; Yao X; Zhang Z; Wang F; Sun G; Cui BB; Dong X; Zhao Y
    Biomed Res Int; 2014; 2014():236361. PubMed ID: 25243122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.
    Gallois C; Taieb J; Le Corre D; Le Malicot K; Tabernero J; Mulot C; Seitz JF; Aparicio T; Folprecht G; Lepage C; Mini E; Van Laethem JL; Emile JF; Laurent-Puig P;
    Clin Cancer Res; 2018 Oct; 24(19):4745-4753. PubMed ID: 29921730
    [No Abstract]   [Full Text] [Related]  

  • 13. Methylator phenotype in colorectal cancer: A prognostic factor or not?
    Gallois C; Laurent-Puig P; Taieb J
    Crit Rev Oncol Hematol; 2016 Mar; 99():74-80. PubMed ID: 26702883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
    Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
    Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
    Kim JH; Bae JM; Cho NY; Kang GH
    Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the CpG island methylator phenotype on survival outcome in colon cancer.
    Kang KJ; Min BH; Ryu KJ; Kim KM; Chang DK; Kim JJ; Rhee JC; Kim YH
    Gut Liver; 2015 Mar; 9(2):202-7. PubMed ID: 25167802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prognostic CpG score derived from epigenome-wide profiling of tumor tissue was independently associated with colorectal cancer survival.
    Jia M; Zhang Y; Jansen L; Walter V; Edelmann D; Gündert M; Tagscherer KE; Roth W; Bewerunge-Hudler M; Herpel E; Kloor M; Ulrich A; Burwinkel B; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M
    Clin Epigenetics; 2019 Jul; 11(1):109. PubMed ID: 31340858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.
    Kim JH; Cho NY; Bae JM; Kim KJ; Rhee YY; Lee HS; Kang GH
    Int J Clin Exp Pathol; 2015; 8(2):1920-8. PubMed ID: 25973084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
    Overman MJ; Adam L; Raghav K; Wang J; Kee B; Fogelman D; Eng C; Vilar E; Shroff R; Dasari A; Wolff R; Morris J; Karunasena E; Pisanic TR; Azad N; Kopetz S
    Ann Oncol; 2018 Jan; 29(1):139-144. PubMed ID: 29069279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers.
    Vedeld HM; Merok M; Jeanmougin M; Danielsen SA; Honne H; Presthus GK; Svindland A; Sjo OH; Hektoen M; Eknaes M; Nesbakken A; Lothe RA; Lind GE
    Int J Cancer; 2017 Sep; 141(5):967-976. PubMed ID: 28542846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.